For the treatment of cats newly diagnosed with diabetes mellitus to reduce hyperglycaemia and to improve hyperglycaemia-associated clinical signs.
BRENZAVVY — THERACOSBIO, approved 2026-06-03 (NDA214373).
66 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.